What changed in this filing

/stocks — the workspaceLOADING

Item 9A. Controls and Procedures

2026-03-23 compared with 2025-03-20 · 38 added, 29 removed, 161 unchanged (29% of the section changed)

48 unchanged sentences

3.1* Amended & Restated Certificate of Incorporation of Context Therapeutics Inc.

as amended through September 17, 2024 (incorporated by reference to Exhibit 3.2 to the Company's Current Report on Form 8-K (File No.

001-40654), as filed with the SEC on September 17, 2024).

as amended through March 11 , 202 6 .

3.2 Certificate of Correction to the Amended and Restated Certificate of Incorporation, dated March 11, 2026 (incorporated by reference to Exhibit 3.1 to the Company ’ s Current Report on Form 8-K (File No.

001-40654), as fi led with t h e SEC on March 13, 202 6).

3.3 Amended & Restated Bylaws of Context Therapeutics Inc.

21 unchanged sentences

333-256572), as filed with the SEC on May 27, 2021).

Description of Exhibit

Context Therapeutics Inc.

1 unchanged sentence

333-256572), as filed with the SEC on May 27, 2021).

Description of Exhibit

Form of Stock Option Agreement under the Context Therapeutics Inc.

8 unchanged sentences

Amended and Restated Employment Agreement, dated October 22, 2021, between Context Therapeutics Inc.

and Martin Lehr (incorporated by reference to the Company’s Current Report on Form 8-K (File No.

and Martin Lehr (incorporated by reference to Exh ibit 10.1 to the Company’s Current Report on Form 8-K (File No.

001-40654), as filed with the SEC on October 22, 2021).

2 unchanged sentences

001-40654), as filed with the SEC on November 1, 2021).

Securities Purchase Agreement, dated December 1, 2021, by and between Context Therapeutics Inc.

and the purchasers named therein (incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q (File No.

001-40654), as filed with the SEC on December 2, 2021).

Registration Rights Agreement, dated December 1, 2021, by and between Context Therapeutics Inc.

and the purchasers named therein (incorporated by reference to Exhibit 10.4 to the Company’s Quarterly Report on Form 10-Q (File No.

001-40654), as filed with the SEC on December 2, 2021).

10.11† Employment Agreement, dated October 22, 2021, between Context Therapeutics Inc.

1 unchanged sentence

001-40654), as filed with the SEC on March 23, 2022).

10.12† Employment Agreement, dated June 9, 2025, between Context Therapeutics Inc.

and Karen Chagin, M.D.

(incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q (File No.

001-40654), as filed with the SEC on August 6, 2025).

10.13 Registration Rights Agreement, dated December 1, 2021, by and between Context Therapeutics Inc.

and the purchasers named therein (incorporated by reference to Exhibit 10.4 to the Company’s Quarterly Report on Form 10-Q (File No.

001-40654), as filed with the SEC on December 2, 2021).

Development and Manufacturing Services Agreement, dated November 7, 2022, between Lonza Sales AG, Lonza AG and Context Therapeutics Inc.

2 unchanged sentences

10.15# First Amendment to the Development and Manufacturing Services Agreement, dated January 9, 2025, between Lonza Sales AG, Lonza AG and Context Therapeutics Inc.

(incorporated by reference to Exhibit 1 0.15 to the Company’s Annual Report on Form 10-K (File No.

001-40654), as filed with the SEC on March 20, 2025).

License Agreement, dated November 7, 2022, between Lonza Sales AG and Context Therapeutics Inc.

1 unchanged sentence

001-40654), as filed with the SEC on November 9, 2022).

Securities Purchase Agreement, dated May 1, 2024, by and between the Company and the Purchasers named therein (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K (File No.

001-40654), as filed with the SEC on May 2, 2024).

10.17# Amendment No.

1 to License Agreement, dated November 3, 2025, between Lonza Sales AG and Context Therapeutics Inc.

(incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q (File No.

001-40654), as filed with the SEC on November 5, 2025).

10.18# License Agreement, dated November 3, 2025, between Lonza Sales AG and Context Therapeutics Inc.

(incorporated by reference to Exhibit 10.

2 to the Company's Quarterly Report on Form 10-Q (File No.

001-40654), as filed with the SEC on November 5, 2025).

10.19 Registration Rights Agreement, dated May 1, 2024, by and between the Company and the Purchasers named therein (incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K (File No.

001-40654), as filed with the SEC on May 2, 2024).

M aster S ervices Agreement , dated October 8, 2021 , by and between Lin k Immunotherapeutics, Inc.

10.20# Master Services Agreement, dated October 8, 2021, by and between Link Immunotherapeutics, Inc.

and Just - Evotec Biologics, Inc.

(as assigned to the Company on July 9 , 2024)

(as assigned to the Company on July 9, 2024) (incorporated by reference to Exhibit 1 0.19 to the Company’s Annual Report on Form 10-K (File No.

001-40654), as filed with the SEC on March 20, 2025).

Description of Exhibit

10.21# Asset Purchase Agreement, dated July 9, 2024, by and between Company and Link (assignment for the benefit of creditors), LLC (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K (File No.

001-40654), as filed with the SEC on July 10, 2024).

Employment Agreement, dated August 1, 2024, between Context Therapeutics Inc.

and Claudio Alberto Dansky Ullmann, M.D.

(incorporated by reference to Exhibit 10.

4 to the Company's Quart erly Report on Form 10-Q (File No.

001-40654), as filed with the SEC on August 7 , 2024).

10.22† Form of Stock Option Agreement (Inducement Grant) of Context Therapeutics Inc.

(incorporated by reference to Exhibit 10.

5 to the Company's Quarterly Report on Form 10-Q (File No.

(incorporated by reference to Exhibit 10.5 to the Company's Quarterly Report on Form 10-Q (File No.

001-40654), as filed with the SEC on August 7, 2024).

Description of Exhibit

10.23† Form of Stock Option Agreement under the Context Therapeutics Inc.

2021 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.

6 to the Company's Quarterly Report on Form 10-Q (File No.

2021 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.6 to the Company's Quarterly Report on Form 10-Q (File No.

001-40654), as filed with the SEC on August 7, 2024).

3 unchanged sentences

10.25 Sales Agreement, dated as of December 2, 2024, by and between Context Therapeutics Inc.

and Leerink Partners LLC (incorporated by re ference to Exhibit 10.1 to the Company ’ s Current Report on Form 8- K (File No.

and Leerink Partners LLC (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No.

001-40654), as filed with the SEC on December 2 , 2024).

C ontext Therapeutics Inc.

Insider Tradi ng Pol icy

10.26 Amendment No.

1 to Sales Agreement, dated as of October 24, 2025, by and between Context Therapeutics Inc.

and Leerink Partners LLC (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No.

001-40654), as filed with the SEC on October 24, 2025).

19 Context Therapeutics Inc.

Insider Trading Policy (incorporated by reference to Exhibit 19 to the Company ’ s Annual Report on Form 10-K (Fi le No .

001-40654 ), as filed with the SEC on March 20, 20 25).

21.1 Subsidiaries of the Company (incorporated by reference to Exhibit 21.1 to the Company’s Registration Statement on Form S-1 (File No.

3 unchanged sentences

31.2* Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or 15a-14(a) under the Exchange Act.

32.1*+ Certification Pursuant to 18 U.S.C.

32.1*+ Certification p ursuant to 18 U.S.C.

Section 1350 of principal executive officer and principal financial officer.

Context Therapeutics Inc.

Compensation Recovery Policy (incorporated by reference to Exhibit 97 t o the Company’s Annual R eport on Form 1 0-K , as filed with the SEC on Ma rch 2 1 , 202 4 ).

Compensation Recovery Policy (incorporated by reference to Exhibit 97 to the Company’s Annual Report on Form 10-K, as filed with the SEC on March 21, 2024).

101 The following financial statements from Context Therapeutics Inc.’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, formatted in Inline XBRL (eXtensible Business Reporting Language):

40 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 9A. Controls and Procedures